DALLAS, October 29, 2014 /PRNewswire/ --
ReportsnReports.com adds Non-Hodgkin Lymphoma Therapeutics in Major Developed Markets to 2020 - New Entrants and Promising Pipeline Widen Targeted and Immunotherapeutic Treatment Options research report to its store. This research provides in-depth insight into the indication. It provides estimates of market size for 2013 along with forecasts until 2020 for the eight major developed markets, which comprises the US, UK, France, Germany, Italy, Spain, Japan and Canada. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of clinical trials including failure rates and pipeline analysis, and analysis of deals relevant to Non-Hodgkin Lymphoma (NHL).
As per this research on Non-Hodgkin Lymphoma Therapeutics in Major Developed Markets to 2020 [http://www.reportsnreports.com/reports/312765-non-hodgkin-lymphoma-therapeutics-in-major-developed-markets-to-2020-new-entrants-and-promising-pipeline-widen-targeted-and-immunotherapeutic-treatment-options.html ] , value of the NHL market is expected to reach $9.2 billion by 2020 from $5.6 billion in 2013 at a modest Compound Annual Growth Rate (CAGR) of 7.4%. The expected launch of promising drugs, including novel small molecule inhibitors and next-generation monoclonal antibodies, as well as the continued use of the current blockbuster, Rituxan/Mabthera (rituximab), will be the key growth drivers. The launch of a premium-priced novel glycol-engineered antibody; obinutuzumab; the personalized vaccine dasiprotimut-T, mTOR inhibitor everolimus, and several kinase inhibitors including idelalisib and ibrutinib (which already gained FDA approval) are expected to have a significant impact on the market size. Additionally, the extension of indications of several already marketed drugs such as Revlimid as a maintenance therapy for DLBCL, Velcade as a front-line therapy for MCL and Adcetris as front-line therapy for CD30 T-cell lymphoma, will fuel the growth during the forecast period.
The emerging treatment challenges in the current treatment landscape (which include, treatment of refractory/relapsed disease and increasing rituximab resistance) are expected to be addressed by the promising NHL pipeline. In spite of a slew of expected approvals the market is set to increase a modest pace due to the patent expiry of the gold-standard therapy during the forecast period.
Products discussed in this research report include Rituxan/Mabthera (rituximab) - Roche, Adcetris (Brentuximab vedotin) - Seattle Genetics/Millennium, Zevalin (ibritumomab tiuxetan) - Spectrum Pharmaceuticals, Revlimid (lenalidomide) - Celgene, Velcade (bortezomib) - Millennium/Johnson-Johnson, Istodax (romidepsin) - Celgene, Zolinza (vorinostat) - Merck, Zydelig (idelalisib/GS-1101) - Gilead Sciences, Imbruvica (ibrutinib) - Pharmacyclics/Janssen Biotech, Beleodaq (belinostat) - Spectrum Pharmaceuticals, Poteligeo (mogamulizumab) - Kyowa Hakko Kirin, Pixuvri (pixantrone dimaleate) - CTI BioPharma, Treanda (bendamustine) + Rituxan (rituximab), CHOP/R-CHOP and CVP/R-CVP. Order a copy of this report at http://www.reportsnreports.com/Purchase.aspx?name=312765 .
The Non-Hodgkin Lymphoma Therapeutics in Major Developed Markets to 2020 report analyzes treatment usage patterns, market characterization, the pipeline, and key licensing and co-development deals in the eight major developed markets of the US, UK, France, Germany, Italy, Spain, Japan and Canada. It includes a brief introduction to NHL, including the disease's pathogenesis, etiology, diagnosis and treatment algorithms. In-depth analysis of currently marketed drugs for NHL, examining their safety, efficacy, treatment patterns and strengths/weaknesses and including a heat map that compares the drugs in terms of safety and efficacy. A comprehensive review of the pipeline for NHL, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market during the forecast period; the pipeline is analyzed on the basis of Phase distribution, molecule type, program type, mechanism of action and molecular target. Additional in-depth analysis of pipeline drug clinical trials by Phase, trial size, trial duration and program failure rate for each molecule type. Multi-scenario forecast data of the market to 2020, taking into account how the market may be affected by the introduction of new drugs, the expiry of key patents on current drugs and the changes in disease epidemiology across the key developed markets. Discussion of the drivers of and barriers to market growth and an in-depth analysis of all licensing and co-development deals that have occurred in the NHL market since 2006 are also provided.
Reasons To Buy This NHL Therapeutics Market Report on Major Developed Regions include:
The report will enhance your decision-making capability by allowing you to:
- Understand the NHL pipeline and the factors that indicate that it is becoming more innovative - Examine detailed profiles of promising pipeline products and gain an insight into how they are likely to compete in the market and who their main competitors will be - Follow the trends in NHL clinical trial size and duration in relation to industry averages and assess the potential risk of future developmental programs according to mechanism of action by considering the recorded clinical trial failure rates - Observe the potential growth patterns expected for the NHL market over the forecast period, identify which countries are expected to make the biggest contribution to this growth, and devise a more effective country strategy through an understanding of key drivers and barriers in the NHL market - Accelerate and strengthen your market position by identifying key companies for strategic partnerships
Another research titled Global Non-Hodgkin Lymphoma Therapeutics Market 2014-2018 is 91 pages report that forecasts the industry to grow at 7.03% during 2013-2018. It says market will observe a high growth in the forecast period. It is due to the availability of the biosimilars at a reduced price across the NHL market. This will be mainly due to the growth of the drug Rituxan in the global market. Apart from that, the market will also grow as a result of the improved diagnostic techniques to detect NHL. Besides, the increase in public awareness about NHL and robust drug pipeline for the treatment of NHL are the major influencers in the growth of the Global Non-Hodgkin Lymphoma Therapeutics market. Companies like Bristol Myers Squibb Co., Celgene Corp., Eli Lilly and Co., F. Hoffman La-Roche Ltd., GlaxoSmithKline PLC, Accredo Health Group Inc., Baxter International Inc., Bayer AG, Cephalon Inc., Eisai Pharmaceuticals Inc., Genelabs Technologies Inc., Hospira Inc., Johnson & Johnson, Merck & Co. Inc., Millenium Pharmaceuticals Inc., Pacira Pharmaceuticals Inc., Pfizer Inc., Sanofi SA and Teva Pharmaceuticals Inc. are discussed in this research available at http://www.reportsnreports.com/reports/291336-global-non-hodgkin-lymphoma-therapeutics-market-2014-2018.html .
Explore more reports on the pharmaceuticals market at http://www.reportsnreports.com/market-research/pharmaceuticals .
ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.
TX, Dallas North - Dominion Plaza, 17304, Preston Road, Suite 800, Dallas 75252
Tel: +1-888-391-5441 email@example.com
Connect With Us on:
Facebook: https: //http://www.facebook.com/pages/ReportsnReports/191441427571689 [https://www.facebook.com/pages/ReportsnReports/191441427571689 ]
Twitter: https: //twitter.com/marketsreports [https://twitter.com/marketsreports ]
RSS/Feeds: http: //http://www.reportsnreports.com/feed/l-latestreports.xml [http://www.reportsnreports.com/feed/l-latestreports.xml ]
Copyright (C) 2014 PR Newswire Europe